Atomoxetine in autism spectrum disorder : no effects on <font color="red">social_1</font> <font color="red">functioning_1</font> <font color="red">;_1</font> some beneficial effects on <font color="red">stereotyped_1</font> <font color="red">behaviors_1</font> <font color="red">,_1</font> <font color="red">inappropriate_1</font> <font color="red">speech_1</font> <font color="red">,_1</font> and <font color="red">fear_1</font> <font color="red">of_1</font> <font color="red">change_1</font> <font color="red">._1</font> 
<br>
<br> UNLABELLED Abstract Objective : The objective of this study was to investigate the short - term treatment effects of atomoxetine on <font color="red">autism_1</font> <font color="red">spectrum_1</font> <font color="red">disorder_1</font> <font color="red">(_1</font> <font color="red">ASD_1</font> <font color="red">)_1</font> <font color="red">symptoms_1</font> in children and adolescents with both ASD and attention - deficit / hyperactivity disorder ( ADHD ) . 
<br> METHODS A total of 97 patients 6 - 17 years of age , with ASD and ADHD , were treated with 1.2 â€‰ mg / kg / day of atomoxetine during an 8 week double - blind placebo - controlled period . Here , we investigated effects on two <font color="red">parent_1</font> <font color="red">-_1</font> <font color="red">based_1</font> <font color="red">secondary_1</font> <font color="red">outcome_1</font> <font color="red">measures_1</font> <font color="red">,_1</font> <font color="red">the_1</font> <font color="red">Aberrant_1</font> <font color="red">Behavior_1</font> <font color="red">Checklist_1</font> <font color="red">(_1</font> <font color="red">ABC_1</font> <font color="red">)_1</font> <font color="red">and_1</font> <font color="red">the_1</font> <font color="red">Children_1</font> <font color="red">'s_1</font> <font color="red">Social_1</font> <font color="red">Behavior_1</font> <font color="red">Questionnaire_1</font> <font color="red">(_1</font> <font color="red">CSBQ_1</font> <font color="red">)_1</font> <font color="red">._1</font> 
<br> RESULTS After 8 weeks of double - blind treatment , atomoxetine administration was associated with significant treatment effects on the <font color="red">ABC_1</font> <font color="red">subscales_1</font> <font color="red">Hyperactivity_1</font> <font color="red">,_1</font> <font color="red">Inappropriate_1</font> <font color="red">Speech_1</font> <font color="red">,_1</font> <font color="red">and_1</font> <font color="red">Stereotypic_1</font> <font color="red">Behavior_1</font> <font color="red">,_1</font> <font color="red">and_1</font> <font color="red">on_1</font> <font color="red">the_1</font> <font color="red">CSBQ_1</font> <font color="red">subscale_1</font> <font color="red">Fear_1</font> <font color="red">for_1</font> <font color="red">Changes_1</font> <font color="red">._1</font> 
<br> CONCLUSIONS Our study results indicate no beneficial effects of atomoxetine on <font color="red">social_1</font> <font color="red">functioning_1</font> <font color="red">._1</font> However , atomoxetine may ameliorate <font color="red">restricted_1</font> <font color="red">and_1</font> <font color="red">stereotyped_1</font> <font color="red">behaviors_1</font> <font color="red">and_1</font> <font color="red">communication_1</font> <font color="red">._1</font> This study has been registered in ClinicalTrials.gov ( www.clinicaltrials.gov ) under registration number NCT00380692 .